Last checked at (Sharecast News) - Biotherapeutics developer Avacta has entered into a collaboration agreement with American firm Adeptrix to develop a high throughput Covid-19 antigen test using its proprietary bead-assisted mass spectrometry (BAMS) platform.
Avacta said on Friday that it would work with Adeptrix to develop and manufacture a coronavirus antigen test that would provide clinicians with a "significant expansion" of the available testing capacity for Covid-19 infection by allowing hospitals to utilise their existing installed base of mass spectrometers that are not currently used for testing.
"Hundreds of samples per day can be analysed by a single technician using BAMS, exceeding the capacity of single PCR machine, making BAMS a very attractive high throughput technique for COVID-19 screening in the clinical setting," said Avacta.
The AIM-listed group added that development of a BAMS test capable of diagnosing someone with Covid-19 would be "a quick process" and said both companies were aiming to have tests ready for clinical validation, regulatory approval and manufacturing in June.
Chief executive Dr Alistair Smith said: "A consensus view is building around the world that hundreds of millions of COVID-19 tests are going to be required per month for a long period, and that the disease will be endemic after the initial pandemic has passed, meaning that testing for COVID-19 is going to be needed for many years."
As of 1315 BST, Avacta shares had shot up 10.16% to 105.20p.
8 Mar 2021 11:06
Avacta confirms efficacy of test on variant Covid-19 strains
(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.
Read more